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Abstract
To investigate if Brain Natriuretic Peptide (BNP) and high-
sensitivity troponin I predict significant arrhythmia, symptomatic
significant arrhythmia and 90-day death and/or Major Adverse
Cardiac Event in Emergency Department (ED) unexplained syn-
cope patients investigated with a 14-day ambulatory electrocardio-
gram (ECG) recorder. Single-centre, prospective, cohort study.
Patients 16 years or over presenting within 6 hours of an episode
of unexplained syncope were fitted with an ambulatory ECG
recorder (Zio® XT monitor) and had high-sensitivity troponin I
and BNP measured on ED admission and 3 hours later. Between
17/11/2015 and 13/06/2017, 86 patients were recruited. 24 had sig-
nificant arrhythmia, 9 symptomatic significant arrhythmia and 26
patients had death and/or Major adverse cardiac events by 90 days.
BNP at admission, three hours and change in BNP and high-sensi-
tivity troponin I at three hours were associated with significant
arrhythmia and serious outcome. BNP >20pg/mL and/or high-sen-
sitivity troponin I above the 99% sex specific centile (M>34ng/L,
F>16ng/L) at 3 hours had a sensitivity of 100% (21/21; 95% CI
81%-100%) and specificity of 43% (16/37; 28%-60%) for signifi-
cant arrhythmia and a sensitivity of 100% (22/22; 95% CI 82%-
100%) and specificity of 44% (16/36; 28%-62%) for serious out-
come both at 90 days. The combination of BNP and high-sensitiv-
ity troponin I at 3 hours shows promise as a potential predictive
marker for serious arrhythmia and serious outcome at 90 days and
deserves further exploration as a rule out test to enable safe dis-
charge of patients from the ED who are at low risk of having car-
diac syncope and subsequent adverse events.
Introduction
Syncope is a common emergency department (ED) presenta-
tion but the underlying diagnosis is not apparent in 30% or more of
patients after assessment and the serious adverse event rate is 7%
at one month.1 Most serious outcomes are due to cardiovascular
causes, which are more likely to be undetected during ED assess-
ment.2 Previous research has aimed to identify clinical parameters
that could risk stratify syncope patients presenting to the ED.1 One
area of study has been assessing if cardiac biomarkers such as
Brain Natriuretic Peptide (BNP) and troponin, which are known to
be associated with cardiac abnormalities, could detect patients at
high risk of cardiac syncope.3-6
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BNP is a natriuretic peptide hormone, released from myocytes
in association with increased pressure on the cardiac muscle wall.3
Evidence from in vivo and in vitro studies indicate that BNP
release also correlates to the presence of cardiac muscle
ischaemia.7 Proving this is a causal relationship is challenging, as
cardiac ischaemia cannot be easily separated from other cardiac
pathology known to raise BNP levels.8,9 Many cardiac diseases can
lead to raised BNP through these pathophysiological mechanisms.3
Current guidelines do not recommend BNP testing for patients
presenting with syncope, although there is evidence that BNP can
be informative in the risk stratification of syncope patients.1,10-14 In
one study, BNP levels greater than 300pg/mL predicted 36% of
serious cardiovascular outcomes and had a 99.8% negative predic-
tive value of all-cause mortality within one month of ED presenta-
tion.1 In another study, a threshold of 40pg/mL detected cardiac
syncope with 82% sensitivity and 92% specificity.11 A specific
threshold value for BNP for cardiac syncope risk has yet to be
established, as highlighted by the different BNP values reported in
research papers.1,10-13 Intra-person variation has also been demon-
strated after syncope.12,13 In patients having an Implantable Cardiac
Defibrillator (ICD) fitted or ICD batteries replaced, Ventricular
fibrillation (VF) was provoked for a few seconds and BNP levels
were measured.13 In 89% of patients, BNP increased after VF and
peaked at an average of 9 hours, evidence that BNP rises after a
cardiac arrhythmia13 This adds a further complexity as any BNP
threshold value may be dependent on blood sampling timing.
Another biomarker that has been researched for potential use
in syncope patients is troponin. Troponin T and I are proteins pres-
ent only in cardiac myocytes.5 They are released into blood when
myocardial tissue is damaged.5 Many medical conditions and pro-
cedures can raise troponin levels,5 yet in clinical practice troponin
is primarily utilised for the diagnosis of Acute Myocardial
Infarction alongside clinical signs or symptoms of cardiac
ischaemia. Previous studies by our group have shown that rises in
troponin concentration are associated with serious outcome,
including death at one month and one year after ED syncope pres-
entation.6,15 Christ et al. identified that 40% of patients with
increased troponin levels had cardiac syncope, and higher troponin
in non-cardiac syncope still correlated with worse prognosis.16
A recent systematic review concluded that cardiac biomarkers
may enhance accuracy of syncope risk stratification if used along-
side other tests.14 This review identified much variation between
studies, including different study designs, definition of Major
adverse cardiac events (MACE) and differing patient populations,
hence limiting conclusions.14 This current study offers a novel
opportunity to analyse both BNP and troponin biomarkers in combi-
nation with arrhythmias detected on an ambulatory electrocardio-
gram (ECG) recorder (Zio® XT monitor). The aim of this study is
to investigate if BNP and high-sensitivity troponin I predict signifi-
cant arrhythmia, symptomatic significant arrhythmia and 90 day-
outcome (death and/or MACE) in unexplained ED syncope patients.
Materials and Methods
Study design and setting
This was a single-centre, prospective, cohort study. The study
was conducted in the ED of the Royal Infirmary of Edinburgh
(RIE): a United Kingdom tertiary centre with 120,000 adult atten-
dances per annum. The study was granted ethical approval by the
South East Scotland Research Ethical Committee (15/SS/0072).
Written consent was obtained from all patients.
Study population
Patients aged 16 years or over who presented within 6 hours of
an episode of syncope and whose syncope remained unexplained
after ED assessment were enrolled. Exclusion criteria were obvi-
ous underlying cause after ED assessment (defined as: i) clinical
history of vasovagal syncope i.e. pre-syncope symptoms and low-
risk patient according to European Society of Cardiology guide-
lines current at the time of study commencement;17 ii) arrhythmia
on ED ECG thought to have caused syncope; iii) arrhythmia on
pre-hospital ECG causing syncope; iv) pulmonary embolism diag-
nosed on Computed Tomography Pulmonary Angiogram (or
equivalent e.g. symptoms of PE plus positive leg
Ultrasound/Ventilation/perfusion scan/echo); v) postural hypoten-
sion (postural drop >20 mmHg in ED with symptoms during test
and suggestive history); vi) Myocardial Infarction;18 vii)
Computed Tomography brain or clinical signs/symptoms in ED
showing cerebrovascular accident or subarachnoid haemorrhage;
viii) evidence of haemorrhage in ED thought to have caused syn-
cope; ix) other obvious cause of syncope apparent in ED: alcohol
or illicit drugs as presumptive cause, epileptic seizure as presump-
tive cause (seizure activity with a >15 min witness reported post-
ictal phase), stroke/transient ischemic attack as presumptive cause,
preceding head trauma, hypoglycemia as presumptive cause; or x)
no consent available i.e. patient lacking capacity, previous recruit-
ment into the study or patient in custody or prison.
Standardized patient assessment
Potentially eligible patients were identified by clinical staff in
the ED and assessed for study inclusion by the attending clinician.
If the patient fulfilled the study eligibility criteria, written consent
was taken. A decision to enroll a patient was not later overturned.
Patients had a Case Report Form completed in the ED, comprising
demographic, historical and examination characteristics, 12-lead
ECG, and radiology and standard laboratory investigations, and
subsequently entered into a specially designed electronic database.
ED tests not part of the study protocol were ordered at the discre-
tion of the treating clinician, and patients were admitted, referred
for outpatient investigation, or discharged according to existing
ED protocols and at the discretion of the treating clinician. If a
patient was admitted the reason for admission was recorded.
All enrolled patients were fitted with an ambulatory ECG mon-
itor (Zio® XT). The Zio® XT monitor is a lightweight, lead-wire
free, single-patient-use ECG monitor that adheres to the left upper
chest and records and stores up to 14 days of continuous, beat-to-
beat ECG. Patients have the option of pressing a trigger button on
the device and filling out a log to document symptomatic events
during their wear duration, which allows for symptom-rhythm cor-
relation in the ECG report. After a patient completes their 14-day
recording, the monitor is removed from the chest and mailed to
iRhythm Technologies, Inc., where the up to 14-day single-channel
recording is analyzed using a combination of proprietary algo-
rithms and review by Certified Cardiac Technicians. The findings
are then reported to the ordering physician in a report that includes
information on several standard arrhythmias, including atrial fib-
rillation and flutter, ventricular tachycardia, supraventricular
tachycardia, atrioventricular pauses, heart block, atrial and ventric-
ular ectopic beats, and other identified arrhythmias. Zio® XT mon-
itors were placed on patients in the ED by a trained research team
member, and were left on for 2 weeks.
Additionally, study participants were also given a diary in
which to record any symptoms occurring during the recording
period e.g. light-headedness/dizziness, syncope/presyncope, and a
Zio® XT monitor satisfaction questionnaire and contact informa-
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tion for the PATCH-ED research team in case of monitor concerns
during the study period. At the end of the study period, the patient
sent the monitor back to the iRhythm Clinical Centre for data pro-
cessing as described and the Zio® XT report was then posted to a
secure web site where it could then be accessed by the Edinburgh
study team.
Any study participant with a serious significant arrhythmia on
the Zio® XT report was contacted immediately and appropriately
referred to the hospital cardiac electrophysiology service.
Serious significant arrhythmia was defined as: i) VF; ii) ven-
tricular tachycardia (VT) ≥120 beats per minute for ≥30 seconds;
iii) symptomatic VT; iv) third/complete degree heart block; v)
symptomatic second degree heart block type II; vi) sinus pause ≥6
seconds; vii) symptomatic bradycardia <40 beats per minute for
≥30 seconds.
Patients were followed up to 90 days after presentation through
hospital and primary care Electronic Patient Record (EPR) sys-
tems. Patients who had left the NHS Lothian area after one month
were contacted by telephone. Serious significant arrhythmia (see
above) and significant arrhythmia were defined based on
Standardized Reporting Guidelines for ED Syncope Risk
Stratification Research.19
Significant arrhythmia was defined as: i) non-symptomatic VT
≥120 beats per minute for <30 seconds; ii) symptomatic sinus
bradycardia <60 beats per minute (but ≥40 beats per minute); iii)
symptomatic sinus bradycardia <40 beats/minute for <30 seconds;
iv) asymptomatic sinus bradycardia <40 beats per minute; v) sick
sinus syndrome with alternating sinus bradycardia and tachycar-
dia; vi) sinus pause ≥3 seconds (but < 6 seconds); vii) symptomatic
Mobitz type I atrioventricular heart block; viii) junctional/idioven-
tricular rhythm; ix) symptomatic supraventricular tachycardia
>100 beats per minute; x) symptomatic atrial flutter/fibrillation
with ventricular rate >100 beats per minute; xi) symptomatic atrial
flutter/fibrillation with ventricular rate <60 beats per minute.
Arrhythmias were also defined as symptomatic (i.e. concurrent
light-headedness/dizziness, syncope/presyncope with arrhythmia)
noted via triggered and diary entries, or asymptomatic. Any signif-
icant symptomatic arrhythmia was discussed with the hospital car-
diac electrophysiology service. Non-recruited but potentially eligi-
ble patients were identified by a daily search of all ED EPRs to
assess for potential recruitment bias. 
Written patient consent included retrieval of leftover patient’s
baseline (admission) routine haematology (EDTA) and biochem-
istry (lithium heparin gel) samples from the RIE laboratory and its
quantification for hs-troponin I (Abbott Architect STAT high-sen-
sitivity troponin I assay performed in RIE laboratory) and BNP
(Abbott TRIAGE point-of-care BNP test performed in the ED).20
The results of these tests were not reported to the clinician. 
Additionally, one 2.7mL EDTA and one 4.7mL lithium heparin
gel sample was taken 3 hours after admission. The lithium heparin
gel sample used to measure troponin (Abbott Architect STAT high-
sensitivity troponin I assay performed in RIE laboratory) and the
EDTA sample was used to measure BNP (Abbott TRIAGE point-
of-care BNP test20 performed in the ED). The results of these tests
were not reported to the clinician.
Outcome measures and assessment
The combined primary endpoint included any of the following
up to 90 days after presentation: significant (including serious sig-
nificant) arrhythmia, symptomatic significant (including serious
significant) arrhythmia and all cause serious outcome. The latter
was defined as death and/or MACE comprising myocardial infarc-
tion,17 significant arrhythmia,19 significant structural heart dis-
ease,19 positive electrophysiology study findings,19 permanent
pacemaker or defibrillator placement, coronary artery bypass graft
or coronary artery stent, cardiac valve surgery, elective cardiover-
sion in the absence of objective evidence that tachyarrhythmia is
responsible for the syncope, balloon-pump insertion, heart trans-
plant, initiation of anti-arrhythmia medical therapy and ventricular
assist device.
                             Article
Table 1. Patient characteristics.
Characteristic                                                                              n
Age/years                                                                                  62.8 +/- 19.5         86
Male sex                                                                                       46 (53)             86
History
Subjective SOB                                                                            6 (7.0)              86
Prodromal/preceding symptoms                                           41 (47.7)            86
Palpitations prior to syncope                                                   3 (3.5)              86
Associated chest pain                                                                5 (5.8)              86
Associated headache                                                                 4 (4.7)              86
Situational symptoms i.e. micturition                                    6 (7.0)              86
Related to GTN use                                                                      0 (0)               86
Related to exertion                                                                    5 (5.8)              86
Witnessed seizure activity                                                        2 (2.3)              86
Estimated Length of Loss of Consciousness/mins         1.5 (1-3)*           58
Past Medical History
Previous episodes of syncope                                               36 (41.9)            86
>1 episode in the last year                                                     17 (19.8)            86
Previous hypertension                                                             35 (40.7)            86
Known ischemic heart disease                                              11 (12.8)            86
Previous myocardial infarct                                                      4 (4.7)              86
Known history of valvular heart disease                                4 (4.7)              86
Previous history of cardiac arrest                                           1 (1.2)              86
Known history of cardiac failure                                             5 (5.8)              86
Pacemaker/Implantable defibrillator                                       0 (0)               86
Examination
Pulse/bpm                                                                                73.7 +/- 14.9         86
Blood sugar /mmol/L                                                               6.6 +/- 2.1           81
Systolic BP /mmHg                                                                138.6 +/- 27.1        86
Diastolic BP/mmHg                                                                75.9 +/- 17.5         86
Postural Drop (>20mmHg on standing)                               4 (7.0)              57
Systolic difference if performed                                        11.1 +/- 10.6         31
Saturation ≤94% on admission                                              25 (29.1)            86
Bradycardia ≤50 in ED or pre-hospital                                  6  (7.0)             86
Heart murmur heard                                                                  6 (7.0)              86
Clinical signs of heart failure present                                   3 (3.5)              86
New neurological signs on examination                                 0 (0)               86
FOB/Melena on PR                                                                       0 (0)               10
Management
Admitted                                                                                      39 (45.3)            86
Discharged                                                                                 47 (54.7)            86
SOB, Shortness of breath; GTN, glyceryl trinitate; BP, blood pressure; FOB, faecal occult blood; PR, per
rectum.. Values are presented as mean +/- SD or n (%) unless stated. *Median (IQR).
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Sample size
This study was a pre-planned secondary analysis of data col-
lected as part of the PATCH-ED study,21 which aimed to recruit
100 patients to inform its primary and secondary aims.
Data analysis and statistics
Two researchers independently reviewed all clinical data and
assigned endpoints with any disagreements resolved by consensus.
Normally distributed variables are presented as mean +/- standard
deviation (SD); otherwise the median and interquartile range were
used as summary measures. Mann-Whitney U tests were used to
compare BNP at admission, 3 hours and delta change with end-
points. Receiver Operator Characteristic (ROC) curve analysis was
used to assess sensitivity and specificity of BNP and hs-troponin I
at different values. Although the product test threshold for the
diagnosis of congestive heart failure is 100pg/mL there are current-
ly no standard normal values for BNP in cardiac syncope. In the
absence of any standard normal values in this patient group, a
threshold value of BNP was chosen with ideal clinical sensitivity
and specificity. A conventional 99th sex specific centile was chosen
as the hs-troponin I threshold to be evaluated in outcome predic-
tion analysis. Further analysis was then performed on the associa-
tion between categorized BNP and hs-troponin I values and out-
come which were compared using Fisher’s exact test.
Results
Between 17/11/2015 and 16/06/2017, 86 patients were recruit-
ed to the study. Figure 1 details the study recruitment diagram.
Baseline characteristics are shown in Table 1 and Figure 2 shows
clinician’s likelihood ratings of underlying cardiac syncope. Mean
age was 62.8 years (range: 18.5 - 97.5 years) and there were 46
males (53%) and 40 females (47%). 
90 day outcomes
At 90 days, 24/86 study participants (27%) had a significant
(including serious) arrhythmia detected by the Zio® XT monitor.
There were 9/86 patients (10%) who had a symptomatic significant
(including serious) arrhythmia and a serious outcome, classified as
a MACE and/or death, occurred in 26/86 patients (30%). 
Timing of sampling
53 of the 86 patients had two BNP samples drawn; the mean
time between sampling was 2.98 hours (range: 0.43-5.9 hours).
Two troponin samples were drawn in 45 patients with a mean time
between sampling of 2.9 hours (range: 0.58-6.2 hours).
Brain Natriuretic Peptide
Median admission BNP was 23.3 pg/mL (IQR 9.0 - 90.6;
n=73) and median three hour BNP was 25.9 pg/mL (IQR 11.8 -
102.9; n=60). Table 2 shows association between study endpoints
and BNP at admission, 3 hours and delta change using ROC curve
analysis. BNP at admission, three hours and change in BNP were
associated with significant arrhythmia and serious outcome.
A three-hour BNP level of 20 pg/mL was chosen for further
analysis and the addition of admission BNP did not improve outcome
prediction enough to justify the extra clinical workload and an addi-
tional blood test for patients. 39 of 60 patients had a BNP level >20
pg/mL at 3 hours which had a sensitivity of 95% (95% CI 74-100),
specificity of 51% (35-67), Positive Predictive Value (PPV) of 51%
(35-67) and Negative Predictive Value (NPV) of 95% (74-100) for
both significant arrhythmia and serious outcome at 90 days. This
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Figure 1. Study recruitment diagram. BNP, Brain Natriuretic
Peptide; ED, emergency department; ECG, electrocardiogram;
CVA, cerebrovascular accident; SAH, subarachnoid haemor-
rhage; ICD, Implantable cardiac defibrillator.
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Figure 2. Frequency of treating clinician’s likelihood of underly-
ing cardiac cause of syncope rating (0 least likely-10 most likely).
MACE, Major adverse cardiac events
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threshold missed an outcome in one patient, a 23-year-old male with
a BNP of 11.3 pg/mL at three hours who had a significant arrhythmia
and serious outcome (non-symptomatic VT ≥120 bpm <30 seconds).
BNP change from admission to three hours had a median difference
of 3.7 pg/mL and median percentage change of 18.5% (n=46). 7
paired samples included a value less than the assay’s lower threshold
of 5. These were resulted as <5 and therefore a BNP change could not
be calculated. Given the test’s coefficient of variation of 9.2-11.4%,
this percentage change cannot only be due to test variation.20
Troponin
Median admission hs troponin I was 3.9 ng/L (IQR 2.0-8.5;
n=71) and median three hour hs-troponin I was 4.9 ng/L (IQR 1.5-
10.0; n=61). 11 of 61 patients had a hs-troponin I above the 99%
sex specific centile at three hours which was associated with sig-
nificant arrhythmia and serious outcome (Table 2). Troponin on
admission was significantly associated with serious outcome
(Table 2). From admission to three hours, delta hs-troponin levels
had median difference of 0.55 ng/L (n=50) and median percentage
change of 15.0% (n=50).
Brain Natriuretic Peptide and Troponin
Given that BNP and troponin at three hours were the time
points most associated with significant arrhythmia and serious out-
come, analysis was carried out to determine if these biomarkers in
combination improved accuracy of outcome prediction (Table 3).
42 of 58 patients had a BNP >20pg/mL and/or high-sensitivity tro-
ponin I above the 99% sex specific centile (M>34ng/L, F>16ng/L)
at 3 hours which had a sensitivity of 100% (21/21; 95% CI 81%-
100%), specificity of 43% (16/37; 28%-60%), PPV of 50% (21/42;
34%-66%) and NPV of 100% (16/16; 76%-100%) for significant
arrhythmia at 90 days and a sensitivity of 100% (22/22; 95% CI
82%-100%), specificity of 44% (16/36; 28%-62%), PPV of 52%
(22/42; 37%-68%) and NPV of 100% (16/16; 76%-100%) for seri-
ous outcome at 90 days.
Discussion
This study has shown that BNP is associated with adverse out-
come in ED syncope patients whose underlying cause is unknown
after ED assessment. High sensitive troponin alone had less value
to predict adverse outcome. A combination of BNP and high sen-
sitive troponin was able to predict all patients with subsequent sig-
nificant arrhythmia and serious outcome with 100% sensitivity.
BNP at admission, 3 hours and delta change was associated
with significant arrhythmia and serious outcome. BNP >20pg/mL
alone at three hours had a NPV of 95% for significant arrhythmia
and serious outcome at 90 days. This threshold of 20pg/mL is
lower than thresholds determined as predictive of cardiac syncope
in other studies.1,11 However in ED clinical practice in this patient
group, an important factor is that any biomarker test must be able
to help the clinician safely rule out a potential adverse outcome and
allow them to safely discharge the patient from the ED. High neg-
ative predictive value and sensitivity are therefore important if the
test is to be used as a useful rule out test. Troponin had limited pre-
dictive value alone for the study endpoints. This finding is similar
to other studies that have shown that raised troponin correlates
with cardiac syncope and serious outcome, though lacks predictive
power independently of other variables.6,16
Combining the biomarker tests resulted in an improved sensi-
tivity, specificity, PPV and NPV compared to BNP alone at 3
hours. However, utilisation of both biomarkers resulted in identifi-
cation of all patients who had a clinical outcome by 90 days. This
study supports the recent meta-analysis that suggested using car-
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Table 2. Association between study endpoints and BNP and troponin at admission, 3 hours and delta change using ROC curve analysis.
                                                                        BNP at admission                           BNP at 3 hours                               Change in BNP
                                                                                 (n=71)   (n=60)                           (n=46)
                                                              ROC AUC                   p value            ROC AUC                  p value      ROC AUC                    p value
Significant arrhythmia                                    0.75 (0.62-0.88)                       0.001*              0.80 (0.69-0.91)                   <0.0001*    0.78 (0.63-0.93)                        0.001*
Symptomatic significant arrhythmia           0.70 (0.49-0.92)                         0.06                 0.75 (0.60-0.90   )                  0.03*       0.76 (0.64-0.91)                         0.03*
Serious outcome (MACE and/or death)    0.77 (0.65-0.89)                    <0.0001*           0.80 (0.69-0.91)                   <0.0001*    0.78 (0.63-0.93)                        0.001*
                                                                      Troponin at admission (n=71)       Troponin at 3 hours (n=61)     Change in Troponin (n=50)
                                                              ROC AUC                   p value            ROC AUC                  p value      ROC AUC                    p value
Significant arrhythmia                                    0.63 (0.49-0.77)                          0.1                 0.71 (0.58-0.84)                      0.01*       0.47 (0.28-0.65)                           0.7
Symptomatic significant arrhythmia           0.44 (0.28-0.59)                          0.6                 0.55 (0.35-0.75)                         0.7          0.37(0.16-0.58)                            0.3
Serious outcome (MACE and/or death)    0.68 (0.54-0.81)                        0.02*               0.74 (0.61-0.86)                     0.003*      0.51 (0.33-0.70)                           0.9
BNP, Brain Natriuretic Peptide; ROC AUC, Receiver Operating Characteristic Area Under Curve (2 decimal places) with 95% CI; MACE, Major adverse cardiac events. P values are ROC AUC asymptotic significance
(null hypothesis; true area = 0.5) and are given to 1 significant figure. *Significant at 5%.
Table 3. Test characteristics for BNP at 3 hours (>20pg/mL) or a raised troponin above the 99% sex specific centile (males >34ng/L,
females >16ng/L) and study outcome.
Study Outcome (n=58+)                                       Sensitivity (%)              Specificity (%)                    PPV (%)                      NPV (%)
Significant arrhythmia                                                               100 (95%CI 81-100)                 43 (95%CI 28-60)                    50 (95%CI 34-66)              100 (95%CI 76-100)
                                                                                                                   21/21                                         16/37                                          21/42                                      16/16
Symptomatic significant arrhythmia                                     100 (95%CI 60-100)                 32 (95%CI 20-47)                     19 (95%CI 9-35)               100 (95%CI 76-100)
                                                                                                                     8/8                                            16/50                                           8/42                                       16/16
Serious outcome at 90 days (MACE +/- death)                 100 (95%CI 82-100)                 44 (95%CI 28-62)                    52 (95%CI 37-68)              100 (95%CI 76-100)
                                                                                                                   22/22                                         16/36                                          20/42                                      16/16
+58 of 86 study patients had both a BNP and high sensitivity troponin drawn at 3 hours. PPV, Positive Predictive Value; NPV, Negative Predictive Value.
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diac biomarkers could aid syncope risk stratification.14
BNP and troponin both exhibited intra-patient variation
between the two samples, with both increases and decreases in bio-
marker at three hours compared to admission baseline. For BNP
this variability cannot be entirely attributed to the test’s margin of
error.20 Intra-patient variation does not seem to be much better than
a three hour result at predicting outcome. A similar situation exists
for troponin; although one participant with a 90-day arrhythmia
outcome had a raised troponin at three hours only after a normal
presentation troponin, further evidence for using this time point.
The mean time between samples was around three hours,
although it is important to note the wide range, which could be
regarded as a limitation of the study. Nevertheless, when transferring
the findings into clinical practice these are representative of real
world practice that is likely to occur in the ED. Our study suggests
that BNP <20pg/mL and/or high-sensitivity troponin I below the
99% sex specific centile (M>34ng/L, F>16ng/L) taken three hours
after admission shows promise as a potential predictive marker for
ruling out serious arrhythmia as the cause of syncope in around 30%
of patients, even with some degree of variability in sample timings. 
Limitations of study
There are a number of limitations to this study. It is single centre,
with a small number of outcomes with no external validation.
However, all patients were thoroughly investigated for arrhythmia
ensuring that we can be very confident in those participants who did
not have an adverse outcome, a problem befalling many syncope
studies. BNP threshold was evaluated in the data set from which it
was derived which will lead to optimism bias in the estimated test
characteristics (i.e. sensitivity, specificity). Whist we are unaware of
any possible selection effect among those patients with two marker
measurements at both time intervals, compared to those with only
one marker or one timing, if present, this may lead to confounding of
the assessment of the predictive value of delta measurements.
Application in clinical practice
Around 780,000 to 1,300,000 patients present to EDs with syn-
cope each year across the UK, of which around 30% do not have a
cause identified after ED assessment. Utilising this biomarker
strategy could potentially inform clinical management of patients
with unexplained syncope and deserves further evaluation in an
external validation study. One clinical strategy that this study
might support is an initial combined biomarker test at 3 hours post
ED attendance, with outpatient ambulatory monitoring for those
with a raised biomarker, and safe discharge from the ED for those
patients with negative biomarkers who are at low risk of having
cardiac syncope and subsequent adverse events.
Conclusions
Syncope is a common medical presentation to the ED, which
may be due to underlying arrhythmia. Challenges remain in differ-
entiating between patients with cardiac syncope and low risk syn-
cope causes. Previous studies have demonstrated that cardiac bio-
markers can assist syncope risk stratification. In this sample all
patients with a serious outcome (MACE or death) and significant
arrhythmia within 90 days of ED presentation were predicted by
BNP>20pg/mL or high-sensitivity troponin I above the 99th centile
taken at three hours post ED admission. This tool deserves further
exploration as a rule out test to enable safe discharge of patients
from the ED who are at low risk of having cardiac syncope and
subsequent adverse events.
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